ClinicalTrials.gg
RecruitingNCT06867302Updated Sep 30, 2026

Dexmedetomidine and Agitation After Nasal Surgery

An interventional study of Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML) and Dexmedetomidine Injection [Precedex] in Nasal Disease and Agitation, Emergence, sponsored by Fayoum University Hospital. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Fayoum University Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Sep 30, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The main objective of study is to compare dexmedetomidine single bolus dose before extubation with continuous infusion as regards their efficacy in mitigating the incidence of emergence agitation in obese adults undergoing nasal surgery.

Read the detailed description

Agitation during emergence from general anesthesia is a potentially serious phenomenon that has not been studied in adults as often as in pediatric population. When agitation, serious self-injury, or violence towards the medical team occur, with the risk of aspiration, bleeding, hypoxia, arrhythmias, or simply pulling the endotracheal tubes, removal of drains or catheters. Moreover, agitated patients are not only at risk of developing complications but also, they are labor intensive as they require more medical attention, rescue drugs, and more attending staff till agitation attack safely subside. Recognized risk factors to develop emergence agitation (EA) in adults include ear, nose, and throat surgery, obesity, sevoflurane anesthesia, endotracheal tube, and history of psychological illness. In adults, adjuvants have been co-administered with general anesthesia in order to negate or reduce the incidence of EA especially in patients with identified risk factors.

dexmedetomidine is a highly selective α2 sympatholytic, has been proposed as an attractive candidate for the prophylaxis of EA. By interacting with α2 receptors in locus coeruleus of the pons, Dex exerts its unique anxiolytic, sedative and sympathetic antagonistic action with no respiratory depression. Moreover, it has pain-modulating effect due to interaction with α2 receptor sites in the dorsal horn and supra-spinal regions.

Nevertheless, there have been conflicting data about Dex optimal dose and time of administration when used as prophylaxis against EA. Indeed, different dosing protocols are associated with over sedation, prolonged extubation time, and delayed post-anaesthesia care unit time.

No premedication. Basic general anesthesia monitoring included electrocardiogram, pulse oximetry, non-invasive arterial pressure, and capnography, were recorded every 5 min. Preoxygenation with 100% oxygen for 5 min was performed before fentanyl 1 μg/kg and propofol 1.5-2 mg/ kg, were administered as induction agents. Intubation with facilitated with atracurium besylate 0.5 mg/ kg. The size of endotracheal tubes was 6.5-7.5 mm, for females and males, respectively. Mechanical ventilation was set on 6 ml/kg tidal volume, and respiratory rate was adjusted to keep end-tidal CO2 between 35 and 40 mmHg, in 50% O2/air. All patients at induction were given dexamethasone 4 mg i.v., ondansetron, 4 mg i.v to prevent post-operative nausea and vomiting, plus Ringers lactate solution 6 mg/ kg drip for basic volume maintenance. Blood loss was compensated for with Ringers lactate, intraoperatively. Maintenance of anesthesia was carried out with Isoflurane, regulated at 2-3%, Titrated incremental doses of atropine 0.5 mg, esmolol 10 mg, and ephedrine 6 mg were given i.v., when HR ≤ 45, HR ≥ 120 and MAP ≤ 60, in the mentioned order. ketorolac 30 mg was given I.M., at the time of nasal packing.

When surgery was finished, gentle suction was attempted, non-depolarizing muscle relaxant reverse with atropine, 0.5 mg and neostigmine 0.02 mg/kg was given. Next, isoflurane was turned off and respiration was then converted back to manual ventilation with 100% oxygen at 7 L/min. The patients were not disturbed, except by continual verbal requests to open their eyes. All other stimuli were prevented. Extubation was done when patients were able to breathe spontaneously and interact with verbal demands. When patients were awake, calm, and sedated, they were transferred to the PACU. Patients were discharged from the PACU when their Aldrete score was ≥ 9.

Statistical analysis:

Statistical analysis will be conducted using IBM SPSS Statistics 22 (IBM Corporation, USA). The normal distribution of data will be assessed by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Mean and standard deviation will be used as descriptive statistics for normally distributed numerical variables, while median and interquartile range (25th to 75th percentiles) will be used as descriptive statistics for non-normally distributed numerical variables. In addition, Chi-square test or fisher exact test will be employed to test the significance between categorical variables as appropriate. Independent t test will be employed for numerical data that exhibited normal distribution, whereas the Mann-Whitney test will be used for numerical data that did not adhere to normal distribution. A significance level of p \< 0.05 will be deemed to be statistically significant.

02

Conditions studied

  • Nasal Disease
  • Agitation, Emergence

Keywords

  • Dexmedetomidine
  • Emergence agitation
  • Nasal surgery
03

In context

Nose Diseases

22 studies on the registry are indexed under Nose Diseases; 9 are open to participants now.

This study's planned enrollment of 50 is below the median of 99 across 18 interventional studies indexed under Nose Diseases.

Browse Nose Diseases studies →

Lead sponsor

Fayoum University Hospital is the lead sponsor of 77 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) Ⅰ or II
  • Adults with (BMI) \< 30 Kg/m
  • Underwent elective nasal surgery.

Exclusion criteria

Exclusion Criteria:

  • Significant comorbidity like hepatic, renal, or cardiac disease
  • Auditory impairment
  • Cognitive dysfunction
  • Substance abuse
  • Allergy to the studied medicines
  • Planned intensive care admission after the surgery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Bolus group

    single dose 0.5 µg/kg in 15 ml saline over 10 min , started 15 minutes before end of surgery

    Drug: Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)

  • Experimental
    Infusion group

    Infusion of dexmedetomidine at a dose of 0.5 µg/kg/h without loading dose all through intraoperative time

    Drug: Dexmedetomidine Injection [Precedex]

Interventions

  • DrugDexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)

    Drug page: DexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    An infusion given all through intraoperative time

    Also known as: Dexmedetomidine infusion

  • DrugDexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single dose given 15 minutes before end of surgery

    Also known as: Dexmedetomidine bolus

06

What researchers measure

Primary outcomes

  1. Degree of emergence agitation by Richmond Agitation Sedation Scale (RASS)

    RASS is a 10-point scoring system used to assess patient's level of agitation and sedation: 4 levels for agitation, 1 level for normal (alert and calm), and 5 levels of sedation

    Time frame: 5 minutes after operation

Secondary outcomes

  1. Intraoperative heart rate

    Beats / minute

    Time frame: Every 15 minutes along operation

  2. Intraoperative mean arterial blood pressure

    mmHg

    Time frame: Every 15 minutes along operation

  3. Time of first rescue analgesic

    in minutes in minutes

    Time frame: 5 minutes before first analgesic request

  4. Extubation time

    time interval between shutting off anesthetics to extubation (in minutes)

    Time frame: 3 minutes after removal of endotracheal tube

  5. Postanesthesia care unit time

    time interval from admission to PACU till patient scored ≥ 9 on Aldrete scale (ready to discharge)

    Time frame: 5 minutes after discharge from recovery unit

  6. Incidence of use of midazolam

    Yes or no

    Time frame: 2 minutes after occurence of emergence agitation

  7. Numerical rating score (NRS)

    10 point scale where zero meaning "no pain" and 10 meaning "the worst pain imaginable"

    Time frame: Every 10 min in postanesthesia care unit

  8. Total amount of rescue analgesic

    in milligram

    Time frame: 24 hours postoperative

  9. Boezaart Surgical Field Grading Scale

    endoscopically using the six-point score (0-5 Scale) where 0 - No bleeding, 1 - Slight bleeding, no suctioning needed, 2 - Slight bleeding, occasional suctioning needed, 3 - Moderate bleeding, frequent suctioning needed, visibility maintained, 4 - Heavy bleeding, constant suctioning needed, visibility impaired, 5 - Severe bleeding, uncontrolled, surgery impossible

    Time frame: 2 hours intraoperatively

  10. Incidence of bradycardia

    Yes or no

    Time frame: 2 hours intraoperatively

  11. Incidence of hypotension

    Yes or no when mean arterial blood pressure below 60 mmHg

    Time frame: 2 hours intraoperatively

  12. Incidence of nausea

    Yes or no

    Time frame: 24 hours postoperative

  13. Incidence of vomiting

    Yes or no

    Time frame: 24 hours postoperative

Other outcomes

  1. Age

    in years

    Time frame: 5 minutes before entering operation department

  2. Sex

    Male of female

    Time frame: 5 minutes before entering operation department

  3. Weight

    In kilogram

    Time frame: 5 minutes before entering operation department

  4. Height

    In centimeter

    Time frame: 5 minutes before entering operation department

  5. Duration of surgery

    In minutes

    Time frame: 5 minutes after end of surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yu D, Chai W, Sun X, Yao L. Emergence agitation in adults: risk factors in 2,000 patients. Can J Anaesth. 2010 Sep;57(9):843-8. doi: 10.1007/s12630-010-9338-9. Epub 2010 Jun 5. PubMed 20526708 ↗
  • Hudek K. Emergence delirium: a nursing perspective. AORN J. 2009 Mar;89(3):509-16; quiz 517-9. doi: 10.1016/j.aorn.2008.12.026. PubMed 19326585 ↗
  • Kim HJ, Kim DK, Kim HY, Kim JK, Choi SW. Risk factors of emergence agitation in adults undergoing general anesthesia for nasal surgery. Clin Exp Otorhinolaryngol. 2015 Mar;8(1):46-51. doi: 10.3342/ceo.2015.8.1.46. Epub 2015 Feb 3. PubMed 25729495 ↗
  • Lepouse C, Lautner CA, Liu L, Gomis P, Leon A. Emergence delirium in adults in the post-anaesthesia care unit. Br J Anaesth. 2006 Jun;96(6):747-53. doi: 10.1093/bja/ael094. Epub 2006 May 2. PubMed 16670111 ↗
  • Zhu M, Wang H, Zhu A, Niu K, Wang G. Meta-analysis of dexmedetomidine on emergence agitation and recovery profiles in children after sevoflurane anesthesia: different administration and different dosage. PLoS One. 2015 Apr 13;10(4):e0123728. doi: 10.1371/journal.pone.0123728. eCollection 2015. PubMed 25874562 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2025 (actual). Primary completion is estimated for Nov 2026, 15 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Mar 2025 → Aug 2025, primary completion Sep 2025 → Nov 2026 and completion Oct 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 10, 2025
StartActual
Aug 1, 2025was Mar 2025
Primary completionEst.
Nov 1, 2026was Sep 2025
CompletionEst.
Dec 1, 2026was Oct 2025
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Fayoum University Hospital · Al Fayyum, Egypt
Show 1 removed
  • Fayoum University Hospital · Fayoum, Egypt
Sep 30, 2026
Start date
Mar 1, 2025→Aug 1, 2025
Sep 30, 2026
Primary completion
Sep 1, 2025→Nov 1, 2026
Sep 30, 2026
Study completion
Oct 1, 2025→Dec 1, 2026
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    1 site added, 1 site removed
    Show site
    • Fayoum University Hospital · Al Fayyum, Egypt
    Show 1 removed
    • Fayoum University Hospital · Fayoum, Egypt
    Start date Mar 1, 2025→Aug 1, 2025
    Primary completion Sep 1, 2025→Nov 1, 2026
    Study completion Oct 1, 2025→Dec 1, 2026
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06867302
Lead sponsor
Fayoum University Hospital
Responsible party
Yasser S Mostafa, MD (Lecturer of Anesthesiology, Fayoum University Hospital) — Principal investigator
First posted
Mar 10, 2025
Start date
Aug 1, 2025
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Yasser S Mostafa, MD
Contact
ysm03@fayoum.edu.eg
01010509735 ext. +2
Mohamed A Shawky, MD
Contact
mas14@fayoum.edu.eg
0 109 525 4547 ext. +2
Yasser S Mostafa, MD
principal investigator · Fayoum University
Mohamed A Shawky, MD
study chair · Fayoum University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion